Cancer drug venetoclax takes aim at HIV's secret hiding spots

NCT ID NCT07481175

Recruiting now Disease control Sponsor: Thomas Aagaard Rasmussen Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage trial tests whether venetoclax, a drug used for certain blood cancers, can help eliminate the hidden HIV reservoir. The study enrolls 38 adults newly starting HIV therapy. Participants receive venetoclax in three short cycles while researchers monitor safety and measure changes in the amount of dormant HIV in their cells.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Venetoclax (a drug that promotes cell death by blocking BCL-2)
What this could lead to: If it works, this could point toward a strategy to shrink the hidden HIV reservoir, potentially allowing people with HIV to stop lifelong medication in the future.
What could go wrong: This is a very early Phase 1 trial with only 38 participants. The drug may not reduce the reservoir enough, or could cause side effects. Even if successful, it is not a cure and further studies are needed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV-1 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV-1

Contacts and locations

Locations

Hospital Universitari Germans Trias I Pujol, Department of Infectious Diseases
RECRUITING

Badalona, Spain
Infectious Diseases, Q Research
RECRUITING

Aarhus, 8200, Denmark

More trials for these conditions

Other studies related to the condition(s) this trial covers.